LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients

Sung-Joon Lee, Hannia Campos, Lemuel A. Moye, Frank M. Sacks

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Objective - Triglyceride-rich lipoproteins that contain apolipoprotein CIII (apoCIII) are prominent in diabetic dyslipidemia. We hypothesized that these lipoproteins increase coronary disease risk in diabetic patients beyond that caused by standard lipid risk factors. Methods and Results - Diabetic patients with previous myocardial infarction were followed for 5 years, and 121 who had a recurrent coronary event were matched to 121 who did not. VLDL and LDL that contained or did not contain apoCIII (CIII+ or CIII-) were prepared by immunoaffinity chromatography and ultracentrifugation. IDL was included in the LDL fraction. LDL CIII+, rich in cholesterol and triglyceride, was the strongest predictor of coronary events (relative risk [RR] 6.6, P<0.0001, for 4th versus 1st quartile). LDL CIII+ comprised 10% of total LDL. The main type of LDL, LDL CIII-, was less strongly predictive (RR 2.2, P = 0.07). The increased risk associated with LDL CIII+ was unaffected by adjustment for plasma lipids, apoB, non-HDL cholesterol, or the other VLDL and LDL types. For VLDL CIII+, RR 0.5, P=0.07; for VLDL CIII-, RR 2.3, P=0.046. The presence of apolipoprotein E with CIII on VLDL and LDL did not affect risk. Conclusions - LDL with apoCIII strongly predicts coronary events in diabetic patients independently of other lipids and may be an atherogenic remnant of triglyceride-rich VLDL metabolism.

Original languageEnglish
Pages (from-to)853-858
Number of pages6
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume23
Issue number5
DOIs
Publication statusPublished - 2003 May 1
Externally publishedYes

Fingerprint

Apolipoprotein C-III
Lipids
Lipoproteins
Triglycerides
Cholesterol
oxidized low density lipoprotein
Ultracentrifugation
Apolipoproteins B
Apolipoproteins E
Dyslipidemias
Coronary Disease
Chromatography
Myocardial Infarction

Keywords

  • Apolipoprotein B
  • Apolipoprotein CIII
  • Apolipoprotein E
  • Coronary heart disease
  • Lipoproteins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. / Lee, Sung-Joon; Campos, Hannia; Moye, Lemuel A.; Sacks, Frank M.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 23, No. 5, 01.05.2003, p. 853-858.

Research output: Contribution to journalArticle

@article{b179af25b8d045a9bc04d16eb65f679c,
title = "LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients",
abstract = "Objective - Triglyceride-rich lipoproteins that contain apolipoprotein CIII (apoCIII) are prominent in diabetic dyslipidemia. We hypothesized that these lipoproteins increase coronary disease risk in diabetic patients beyond that caused by standard lipid risk factors. Methods and Results - Diabetic patients with previous myocardial infarction were followed for 5 years, and 121 who had a recurrent coronary event were matched to 121 who did not. VLDL and LDL that contained or did not contain apoCIII (CIII+ or CIII-) were prepared by immunoaffinity chromatography and ultracentrifugation. IDL was included in the LDL fraction. LDL CIII+, rich in cholesterol and triglyceride, was the strongest predictor of coronary events (relative risk [RR] 6.6, P<0.0001, for 4th versus 1st quartile). LDL CIII+ comprised 10{\%} of total LDL. The main type of LDL, LDL CIII-, was less strongly predictive (RR 2.2, P = 0.07). The increased risk associated with LDL CIII+ was unaffected by adjustment for plasma lipids, apoB, non-HDL cholesterol, or the other VLDL and LDL types. For VLDL CIII+, RR 0.5, P=0.07; for VLDL CIII-, RR 2.3, P=0.046. The presence of apolipoprotein E with CIII on VLDL and LDL did not affect risk. Conclusions - LDL with apoCIII strongly predicts coronary events in diabetic patients independently of other lipids and may be an atherogenic remnant of triglyceride-rich VLDL metabolism.",
keywords = "Apolipoprotein B, Apolipoprotein CIII, Apolipoprotein E, Coronary heart disease, Lipoproteins",
author = "Sung-Joon Lee and Hannia Campos and Moye, {Lemuel A.} and Sacks, {Frank M.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1161/01.ATV.0000066131.01313.EB",
language = "English",
volume = "23",
pages = "853--858",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients

AU - Lee, Sung-Joon

AU - Campos, Hannia

AU - Moye, Lemuel A.

AU - Sacks, Frank M.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Objective - Triglyceride-rich lipoproteins that contain apolipoprotein CIII (apoCIII) are prominent in diabetic dyslipidemia. We hypothesized that these lipoproteins increase coronary disease risk in diabetic patients beyond that caused by standard lipid risk factors. Methods and Results - Diabetic patients with previous myocardial infarction were followed for 5 years, and 121 who had a recurrent coronary event were matched to 121 who did not. VLDL and LDL that contained or did not contain apoCIII (CIII+ or CIII-) were prepared by immunoaffinity chromatography and ultracentrifugation. IDL was included in the LDL fraction. LDL CIII+, rich in cholesterol and triglyceride, was the strongest predictor of coronary events (relative risk [RR] 6.6, P<0.0001, for 4th versus 1st quartile). LDL CIII+ comprised 10% of total LDL. The main type of LDL, LDL CIII-, was less strongly predictive (RR 2.2, P = 0.07). The increased risk associated with LDL CIII+ was unaffected by adjustment for plasma lipids, apoB, non-HDL cholesterol, or the other VLDL and LDL types. For VLDL CIII+, RR 0.5, P=0.07; for VLDL CIII-, RR 2.3, P=0.046. The presence of apolipoprotein E with CIII on VLDL and LDL did not affect risk. Conclusions - LDL with apoCIII strongly predicts coronary events in diabetic patients independently of other lipids and may be an atherogenic remnant of triglyceride-rich VLDL metabolism.

AB - Objective - Triglyceride-rich lipoproteins that contain apolipoprotein CIII (apoCIII) are prominent in diabetic dyslipidemia. We hypothesized that these lipoproteins increase coronary disease risk in diabetic patients beyond that caused by standard lipid risk factors. Methods and Results - Diabetic patients with previous myocardial infarction were followed for 5 years, and 121 who had a recurrent coronary event were matched to 121 who did not. VLDL and LDL that contained or did not contain apoCIII (CIII+ or CIII-) were prepared by immunoaffinity chromatography and ultracentrifugation. IDL was included in the LDL fraction. LDL CIII+, rich in cholesterol and triglyceride, was the strongest predictor of coronary events (relative risk [RR] 6.6, P<0.0001, for 4th versus 1st quartile). LDL CIII+ comprised 10% of total LDL. The main type of LDL, LDL CIII-, was less strongly predictive (RR 2.2, P = 0.07). The increased risk associated with LDL CIII+ was unaffected by adjustment for plasma lipids, apoB, non-HDL cholesterol, or the other VLDL and LDL types. For VLDL CIII+, RR 0.5, P=0.07; for VLDL CIII-, RR 2.3, P=0.046. The presence of apolipoprotein E with CIII on VLDL and LDL did not affect risk. Conclusions - LDL with apoCIII strongly predicts coronary events in diabetic patients independently of other lipids and may be an atherogenic remnant of triglyceride-rich VLDL metabolism.

KW - Apolipoprotein B

KW - Apolipoprotein CIII

KW - Apolipoprotein E

KW - Coronary heart disease

KW - Lipoproteins

UR - http://www.scopus.com/inward/record.url?scp=0038222533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038222533&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.0000066131.01313.EB

DO - 10.1161/01.ATV.0000066131.01313.EB

M3 - Article

C2 - 12637336

AN - SCOPUS:0038222533

VL - 23

SP - 853

EP - 858

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 5

ER -